EAHP represents over 29,000 hospital pharmacists across 36 member countries. EAHP represents and develops the hospital pharmacy profession within Europe in order to ensure the continuous improvement of care and outcomes for patients in the hospital setting. This is achieved through science, research, education, practice, as well as sharing best-practice and responsibility with other healthcare professionals.
The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
The EAHP staff supports the Board in executing EAHP’s mission. The Staff assists in financial management, events organisations, policy activities and all EAHP projects. The EAHP staff works closely with EAHP’s members and ensures the effective communication all relevant stakeholders.
The first member countries were Belgium, Britain, Denmark, France, the Federal Republic of Germany and The Netherlands in 1972. EAHP has now 36 EAHP members and 2 Associate Members. EAHP is open to countries members of the Council of Europe and since 2022 to organisations representing the interests of hospital pharmacists from outside the Council of Europe (Associate Membership)
EAHP’s structure is also composed by different standing committes: EAHP Scientific Committee, EAHP Education Executive Committee and the EAHP CTF Steering Committee.
At EAHP, we are committed to transparency in our governance, ethical standards, and funding practices. This section provides open access to our foundational documents, including the EAHP Statutes, Code of Conduct, and Funding Sources. By sharing these resources, we aim to uphold accountability and foster trust with our members, partners, and the public.
Keep up with all EAHP’s events and webinars. Contact the team at info@eahp.eu should you have any questions about upcoming events or activities.
Here you can find all upcoming events organised by EAHP and by all its members and associate members. Do not hesitate to contact the events team at events@eahp.eu should you have any questions about the organisation of these events.
Hospital pharmacists conduct a critical role in the care of patients in hospitals. Learn more about what they do here and in all the pages under Hospital Pharmacy practice and Policy.
Self-Assessment
SILCC
Closed SIGs
EAHP brings together experts from many areas of hospital pharmacy practice providing and highlighting good local sustainable practices as that can be up-scaled and shared with other countries. The EAHP Working Group on Sustainability has the aim of reducing the environmental burden of the hospital pharmacy services.
The European Association of Hospital Pharmacists (EAHP), and its 36 member country platforms are creating a Common Training Framework for the hospital pharmacy education in Europe. The goal of this project is to allow the free movement of hospital pharmacists within the European Union.
The European Association of Hospital Pharmacists (EAHP) and the European Society of Clinical Pharmacy (ESCP) have collaboratively developed the Oath to Society. The Oath to Society is all encompassing and acts as a contract for excellence in providing compassionate patient care, working as part of the healthcare team and advancing the pharmacy profession, and showcasing how clinical and hospital pharmacists work every day
A day created to highlight the importance and to celebrate the work done by hospital pharmacies. This day celebrates all hospital pharmacy teams.
Catch up with EAHP’s press releases
Find all EAHP relevant publication like the EAHP Surveys, annual reports and the history books.
The European Journal of Hospital Pharmacy (EJHP) is the only official journal of the European Association of Hospital Pharmacists (EAHP) and is committed to advancing the science, practice and profession of hospital pharmacy. As the premier communication platform for hospital pharmacists worldwide, EJHP is a major source for continuing education as well as updates on advances in the practice and standard of pharmaceutical care for patients.
When EAHP and Hospital pharmacists appear in the news.
EAHP publishes a monthly EU monitor with updates about the latest EAHP initiatives and information relevant for the hospital pharmacy profession.
Sponsor Channel
The Sponsor Channel is designed to maximise visibility and engagement, allowing sponsors to connect with the hospital pharmacy community and partners in a dynamic and interactive environment. From product demonstrations to networking sessions, the Sponsor Channel offers a range of opportunities for sponsors to showcase their offerings and generate leads in the new EAHP Website.
114
Jenzer, Helena
ACPE UAN: 0475-0000-19-014-L04-P. A knowledge based activity.
Linked to EAHP Statements
Section 1 – Introductory Statements and Governance: Statements 1.1, 1.3, 1.6
Section 2 – Selection, Procurement and Distribution: Statements 2.1, 2.2, 2.5, 2.6, 2.7
Section 3 – Production and Compounding: Statements 3.1, 3.2, 3.3, 3.4, 3.5,
Section 4 – Clinical Pharmacy Services: Statements 4.1, 4.2, 4.3, 4.4, 4.8
Section 5 – Patient Safety and Quality Assurance: Statements 5.1, 5.2, 5.3, 5.5, 5.6, 5.11
Section 6 – Education and Research: Statement 6.5
Abstract
Inaccessibility to quality medical products is still a neglected issue, whereas current vulnerabilities of the supply chain of the medicines admitted to the market are mapped by several publications. Access is a complex health and development challenge which depends on many factors. Convincing approaches to improve both access to and availability of medicines are scarce. Non-availabilities of essential medicines are recognised as a more and more worsening fact. To evaluate the most promising coping strategies, dependencies from third parties as well as ways to develop an efficient pharmaceutical supply chain of essential medicines should be assessed. Access might be opened by compassionate use and by hospital pharmacy production. Astonishingly, for coping strategies, hospital pharmacy production is not figuring among the highest priorities. However, the revised Swiss Federal Act on Medicinal Products and Medical Devices and its ordinances are taking into consideration the worsening shortages problems and underlines the importance of hospital pharmacy production to cope with shortages and inaccessibilities.
A major factor delaying access that is often overlooked is the marketing authorisation process that may last up to 7 years in some low and lower-middle income countries – from submission to approval of a dossier in one of the listed regulatory authorities, followed by WHO pre-qualification and then from submission to approval in the target countries. Swissmedic, the Swiss Agency for Therapeutic Products has launched an authorisation procedure to tackle this problem: The Swissmedic Marketing Authorisation for Global Health Products (MAGHP) procedure. It is accessible to representatives of regulatory authorities in resource-constrained countries and the WHO. They can follow the MAGHP procedure, provide expert input and gain confidence in its outcome. Through the participation, the timelines for the WHO-PQ listing and marketing authorisation by NMRAs shall be significantly reduced. Overall, this would lead to a faster access to those medicines for the patients in need.
This seminar focuses on options to improve accessibility to medicines and to reduce the hospital pharmacist’s dependence on third parties of the supply chain in different settings.
Learning objectives
After the seminar, participants should be able to:
• discuss the Swissmedic Marketing Authorisation for Global Health Products (MAGHP) procedure to facilitate of market access;
• consider suitable medicines to be easily prepared in hospital pharmacies;
• assess the feasibility of early access and compassionate use.
Educational need addressed
Drug shortages have been a threatening challenge for hospital pharmacist’s mission to supply medicines to patients. Whereas in shortage situations the supply chain is disrupted and medicines not available for a limited time, parts of populations and/or weakest special patient groups suffer from inaccessibility to medicines supply, namely patients with orphan diseases or patients in low- and middle-income countries. These countries further depend on human and financial resources in order to develop an efficient pharmaceutical sufficient supply chain.
Although ethical justification to provide medicines is recognised, it is still unclear how to optimally implement actions to provide essential medicines worldwide to all patient groups.
In this seminar, tools to improve accessibility and availability are described. Hospital pharmacist might assume an ethical and social responsibility to participate in programmes to improve medicine accessibility.
Keywords: (In-)Accessibility to registered medicines, investigational medicines, early accesses (parallel trial, compassionate use), (in-)available (orphan) drugs, shortages, bridging supply chain disruptions by hospital pharmacy production, international relations, bilateral coordination, development coordination, Bill & Melinda Gates Foundation.
